Funding Opportunity RFA-AA-22-002 from the NIH Guide for Grants and Contracts. This FOA uses the NIH Comprehensive Research Center (P60) mechanism to support an integrated, broad-based multidisciplinary, multi-investigator, long-term program of research and research support activities planned around a specific major research theme.

Notice NOT-DE-22-008 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-22-018 from the NIH Guide for Grants and Contracts. The NIH Directors Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative research towards the ultimate goal of enhancing human health. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigators research program or elsewhere. The NIH Directors Pioneer Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.

Notice NOT-OD-22-111 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-094 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-096 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-162 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications to support cancer epidemiology research in established cohort studies, defined as studies that have achieved their initial planned recruitment goal. Applications must include hypothesis-based research using data from an established cohort study and are expected to include support for cohort maintenance, continued follow-up, and sharing of the existing resources in addition to addressing research questions across the cancer control continuum.

Funding Opportunity RFA-AI-22-024 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to enroll large, digitally-maintained cohorts of people with HIV-1 (PWH) in the United States which employ sampling strategies that ensure meaningful enrollment of participants who report prior gaps in HIV care engagement and/or lack of sustained viral suppression (VS). The goal is to follow the research cohort over time to prospectively investigate trajectories of HIV care engagement and viral suppression, as well as the temporal antecedents and multilevel factors that drive changes in care engagement, antiretroviral adherence, and viral suppression. Researchers may test strategies for improved methods of screening, enrollment, and retention of cohort participants. Projects should seek to inform future interventions to promote sustained engagement in HIV care and sustained HIV viral suppression, and additionally have the option of testing digitally-delivered interventions toward that end.

Funding Opportunity PAR-22-150 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support an IDeA Clinical Research Resource Center (I-CRRC) that addresses two specific needs for increasing capacity to conducting clinical trials and complex observational studies in IDeA states. I-CRRC will 1) strengthen communication and develop collaborations between health research institutions in IDeA-eligible states and clinical trial sponsors, and 2) develop clinical trial and observational study coordinators with the knowledge and skills to manage clinical studies.

Funding Opportunity PAR-22-149 from the NIH Guide for Grants and Contracts. The NEI uses U01 cooperative agreement awards to support investigator-initiated early-stage clinical trials that are greater than minimal risk and typically are Phase I or II trials. The risk level of the U01 trial requires appropriate performance oversight and safety monitoring. For purposes of this FOA, the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders.

Notice NOT-DA-22-057 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-22-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Cystic Fibrosis (CF) Research and Translation Core Centers. CF Research and Translation Core Centers are designed to support both basic and clinical research on Cystic Fibrosis. CF Research and Translation Core Centers support three primary research-related activities: Research Core services; a Pilot and Feasibility program; and an Administrative Core with an enrichment program. Core Centers provide shared resources to support research to develop and test new therapies for CF and to foster collaborations among institutions with a strong existing research base in CF. The NIDDK currently supports seven CF Research and Translation Centers located at institutions with documented programs of research excellence in basic and clinical CF Research. Information about the currently funded CF Research and Translation Centers may be found at:https://www.niddk.nih.gov/research-funding/research-programs/cystic-fibrosis-research-translation-centers or https://www.cysticfibrosiscenters.org/.

Funding Opportunity PAR-22-131 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics / imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for: (1) the early detection of organ confined premetastatic aggressive cancer, and, (2) identifying precancerous lesions associated with a subsequent lethal phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions by improving detection sensitivity and specificity of integrated multiparametric platforms. For example, N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and/or digital pathomics or glycomic, or metabolomic imaging using analytic strategies such as artificial intelligence or virtual reality visualization techniques. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of potentially lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.

Notice NOT-MH-22-230 from the NIH Guide for Grants and Contracts

Notice NOT-GM-22-034 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MD-22-009 from the NIH Guide for Grants and Contracts. This initiative will support research projects that examine innovative approaches and strategies to prevent, test and treat HIV among health disparity populations or subgroups within primary care settings located in geographic areas with a high rate of new infections in the United States.

Funding Opportunity PA-22-168 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to inform Agency for Healthcare Research and Quality (AHRQ) grantees holding active AHRQ awards that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the competing application was submitted. Although requests for administrative supplements may be submitted to this NOFO, there is no guarantee that funds will be available from the awarding agency for any specific grant. Applicants are encouraged to discuss potential requests with the assigned AHRQ staff contacts for their project prior to submission.

Funding Opportunity PAR-22-136 from the NIH Guide for Grants and Contracts. The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers.

Funding Opportunity RFA-AG-23-016 from the NIH Guide for Grants and Contracts. The National Institute on Aging (NIA) invites outstanding graduate students from a wide range of broad research areas who are interested in receiving aging-related postdoctoral training to apply to this Funding Opportunity Announcement (FOA). This FOA seeks to foster the development of research and clinician scientists in the following areas: genetic, biological, clinical, epidemiological, neuroscience, behavioral, social, and economic research on aging, both basic and translational. To accomplish the goal, successful applicants will be awarded the Transition to Aging Research Award for Predoctoral Students. The purpose of the award is to recruit and retain emerging investigators in aging research. This two-phase award will allow awardees to complete doctoral dissertation projects and provide a variety of training supports to facilitate the smooth transition of doctoral graduates into competitive, aging-focused postdoctoral positions.

Funding Opportunity RFA-RM-22-017 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support the establishment of a Translational Coordination and Dissemination Center (TCDC) for the NIH Somatic Cell Genome Editing (SCGE) Consortium. In its second phase (FY2023-2027), the SCGE program will accelerate the development of genome-editing therapeutic agents by: facilitating IND-enabling studies; establishing pathways to regulatory approval; and disseminating successful strategies for initiating first in human clinical trials. In addition to this TCDC, the Consortium will include three components (development of technology/assays that support IND-submissions, optimize genome editing-based therapeutic leads for safety and efficacy and conduct platform clinical trials using genome editing technologies in 1 disease) which together will accelerate the optimization of promising clinical candidates toward IND filings and future first in human clinical trials. The TCDC is expected to lead consortium-wide activities that facilitate intra-consortium collaborations and that support broad dissemination strategies for regulatory submission. The TCDC will develop a publicly available online platform for data collection and dissemination of consortium-wide activities including stewardship and preservation of data generated by SCGE in Phase I.